GIS Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$61.91 |
| 52 Week High | US$80.08 |
| 52 Week Low | US$61.90 |
| Beta | 0.20 |
| 1 Month Change | -8.39% |
| 3 Month Change | -22.61% |
| 1 Year Change | -19.45% |
| 3 Year Change | 12.34% |
| 5 Year Change | 7.76% |
| Change since IPO | 355.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| GIS | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.5% | -4.9% | -1.5% |
| 1Y | -19.5% | -19.9% | 0.9% |
Return vs Industry: GIS matched the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: GIS underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| GIS volatility | |
|---|---|
| GIS Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GIS's share price has been volatile over the past 3 months.
Volatility Over Time: GIS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| GIS fundamental statistics | |
|---|---|
| Market cap | €78.41b |
| Earnings (TTM) | €5.32b |
| Revenue (TTM) | €25.48b |
14.6x
P/E Ratio3.0x
P/S RatioIs GIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GIS income statement (TTM) | |
|---|---|
| Revenue | US$27.12b |
| Cost of Revenue | US$6.02b |
| Gross Profit | US$21.10b |
| Other Expenses | US$15.43b |
| Earnings | US$5.67b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 4.54 |
| Gross Margin | 77.80% |
| Net Profit Margin | 20.89% |
| Debt/Equity Ratio | 109.8% |
How did GIS perform over the long term?
See historical performance and comparison